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Abstract
In the aftermath of a methicillin-resistant Staphylococcus aureus (MRSA) ST22 hospital outbreak, we investigated the prevalence of long-
term carriage, the efﬁcacy of MRSA decolonization treatment (DT) and the spread of MRSA to households of patients and healthcare
workers (HCWs). Furthermore, we evaluated the efﬁcacy of repeated DT in long-term MRSA carriers. Of 250 index persons (58
HCWs and 192 patients), 102 persons (19 HCWs and 83 patients) and 67 household members agreed to participate. Samples from all
169 persons were taken from the nose, throat, wounds and devices/catheters, and urine samples were additionally taken from index
persons. Samples from companion animals (n = 35) were taken from the nostrils and anus. Environmental sites (n = 490) screened were
telephone, television remote control, toilet ﬂush handle, favourite chair and skirting board beside the bed. Sixteen (19%) patients and
two household members, but no HCWs, were ST22-positive. The throat was the most frequent site of colonization. In a multivariate
analysis, chronic disease (p <0.001) and pharyngeal carriage (p <0.001) were associated with long-term MRSA carriage. MRSA was found
in the environments of four long-term carriers. All animals tested were negative. MRSA-positive households were decolonized using
nasal mupirocin TID and daily chlorhexidine body and hair wash for 5 days. Pharyngeal MRSA carriers also received fucidic acid
(500 mg TID) combined with rifampicin (600 mg BID) or clindamycin (600 mg BID) for 7 days. The home environment was cleaned on
days 2 and 5. At the end of follow-up, ten of 16 long-term carriers and the two household contacts were MRSA-negative. In conclusion,
decolonization of MRSA carriers is possible, but should include treatment of household members and the environment.
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Introduction
For more than 30 years, Denmark has been a low-preva-
lence country for methicillin-resistant Staphylococcus aureus
(MRSA) with less than 1% of MRSA in Staphylococcus aureus
bacteraemias (Ref: http://www.ssi.dk/sw3425.asp). This has
been ascribed to the restricted use of broad-spectrum anti-
microbials and to a rigorous practice of isolation procedures
concerning patients with MRSA in hospitals.
MRSA ST22, also known as EMRSA-15, has shown great
ability to colonize and to survive and spread in humans,
companion animals (i.e. dogs and cats) and hospital environ-
ments [1,2]. In the UK, the MRSA prevalence was low until
the early 1990s but, as a result of the introduction of epi-
demic strains, including ST22 and EMRSA-16, the prevalence
of MRSA in bactaeremias increased from 2% to 42% within
10 years [3]. The rise in MRSA infections resulted in
increased admissions and mortality and extensive costs to
healthcare services and, although different approaches have
been tried, the epidemic clones in the UK are still a matter
of concern to the British healthcare system [4,5]. Pandemic
spread of ST22 has also been reported in Portugal, Australia
and New Zealand [6–8].
Until 2002, ST22 was only observed sporadically in Den-
mark. The small MRSA outbreaks have been contained by a
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search and destroy strategy. In November and December
2002, ﬁve cases were seen in two hospitals in Vejle
County and marked the onset of an outbreak, which, from
November 2002 until December 2005, included 440 persons
infected or colonized with ST22, spa-type t022. During the
ﬁrst 2 years of the outbreak, the only interventions imple-
mented were isolation and campaigns for intensiﬁed hand
hygiene. Decolonization therapy (DT) of patients was not
systematically recommended. The outbreak increased during
2004 and, starting 1 January 2005, infection control strategies
were extended, with screening of patients at admission and
discharge and screening of all healthcare workers (HCWs).
MRSA DT was free of charge for both HCWs and patients
and ﬁnally resulted in curbing of the outbreak.
The present study aimed to perform a follow-up assess-
ment of long-term carriage and evaluate the efﬁcacy of DT.
Furthermore, we looked for spread of MRSA within house-
holds, to pets and to the environment, and we assessed the
efﬁciency of repeated DT in persistent MRSA carriers.
Materials and Methods
Setting
Vejle County, Denmark, has a population of approximately
355 000 inhabitants and is served by a network of six hospi-
tals with 70 000 yearly admissions. Because of hospital spe-
cialization, patients are often transferred between hospitals.
All microbiological specimens, collected in hospitals and by
general practitioners and private specialists, are handled
at one site: the Department of Clinical Microbiology, Vejle
Hospital.
MRSA decolonization treatment during the outbreak
During the ﬁrst 2 years of the ST22 outbreak in Vejle
County, MRSA DT was not systematically recommended to
patient carriers. From the beginning of 2004, the Depart-
ment of Clinical Microbiology started recommending DT to
patients, with mupirocin (2%, TID) and chlorhexidine (4%)
hand wash, for 5 days, occasionally in combination with sys-
temic antimicrobial treatment.
Systemic antimicrobial treatment (Table 1) was mainly
given to patients with DT failure. From 2005 onward, all
patients and HCWs were offered DT free of charge
(Table 1). Relatives were not offered screening and DT.
Inclusion and exclusion criteria
Patients, and their household members, living in Vejle
County, who had been MRSA ST22-positive (infected or
colonized) from November 2002 until December 2005 were
eligible for inclusion. Patients living outside Vejle County
and households of deceased patients were excluded. All
HCWs who had worked at one of the hospitals in Vejle
County and their households were eligible. The study was
accepted by the ethics committee for Vejle and Funen
(S-VF-20050181). All eligible households were contacted by
mail with a letter providing information, an informed con-
sent document and a questionnaire. Nonresponders were
contacted again with a second letter after 6 weeks. Patients
and HCWs were included after having provided their
informed consent.
Clinical and demographic data
All persons positive for MRSA ST22 during the study per-
iod were identiﬁed in the laboratory database at the
Department of Clinical Microbiology, Vejle Hospital. For all
persons (both included and nonparticipants), the database
was checked for DT control samples. Correctly taken
DT control samples were deﬁned as three samples,
marked as MRSA control, from the nose, throat and peri-
neum. These samples could not be taken earlier than
1 week after DT.
TABLE 1. Treatment, cleaning and control recommendations for methicillin-resistant Staphylococcus aureus (MRSA)-positive
persons identiﬁed during the household survey
Topical treatment used for all carriers (National guidelines) Mupirocin 2% ointment for nose, TID plus daily chlorhexidine (4%) body and hair wash for 5 days
Systemic decolonization treatment plus topical treatment
for pharyngeal or urinary MRSA carriage (local guidelines)
Pharyngeal carriers:
fucidic acid 500 mg TID and rifampicin 600 mg BID or clindamycin 600 mg BID for 7 days plus mupirocin
2% ointment and chlorhexidine wash
For children, same treatment but reduction of doses according to weight
Urinary MRSA carriers: systemic treatment according to susceptibility proﬁle, mostly trimethroprim and
change of catheter during treatment plus topical treatment
Cleaning recommendations for all positive households Private towels and facecloths. Linen washed at 90C or as warm as possible
Daily:
Change underwear, towels and facecloths after the shower
Air the rooms, pillows and duvets. Clean door handles, toilet and taps
Day 2 and after treatment:
Change the bed linen for all household members and
Clean all horizontal surfaces. Vacuum clean the house
Control recommendations Control at days 7, 14 and 21 after treatment, and after 6–12 months
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Co-morbidity data and previous MRSA carriage and infec-
tion treatment were collected from the National Patient
Registry, the hospital records and from the general practitio-
ners of patients.
Sampling during household visits
Household screenings were carried out from December
2006 until March 2007 and were performed in 98 house-
holds of 102 persons (four households had two previously
MRSA-positive persons) including 83 patients and 19 HCWs,
and 39 household members of patients and 28 of HCWs.
A total of 35 companion animals (20 dogs, 12 cats and
three horses) from 13 patient households and nine HCW
households were also screened.
Samples from all household members were taken from
the nose, throat and skin lesions using one ﬂocked swab
(Copan, Brescia, Italy) per anatomical site. Each swap was
inoculated directly into 3 mL of tryptic soy broth containing
2.5% NaCl, 3.5 mg/L cefoxitin and 20 mg/L aztreonam (TSB
SSI; SSI Diagnostica, Hillerød, Denmark). Urine samples were
collected from the household index persons, considering the
high frequency of urinary tract infections during the out-
break. A veterinarian collected samples from companion ani-
mals from the nose, anus and skin lesions if present.
Environmental samples were taken from the household’s
telephone, the index person’s favourite chair, the toilet ﬂush
handle, televison remote control and skirting board by the
bed, using Biotrace dip-slides (3M, Glostrup, Denmark) con-
taining a Baird Parker agar with ciproﬂoxacin (the ST22
strain is ciproﬂoxacin-resistant).
Infection control precautions to prevent colonization of
study personnel during study visits were performed accord-
ing to national guidelines (National Board of Health: http://
www.sst.dk/Sundhed3A/MRSA.aspx.), which speciﬁed an
appropriate uniform, gloves when sampling and hand hygiene
with alcohol disinfectants after each visit. The project nurse
was screened for MRSA weekly.
Human samples were processed at Vejle Hospital using
the routine methods for MRSA identiﬁcation. TSB SSI broths
were incubated overnight at 35C and PCR for MRSA was
performed with the broth cultures obtained from all human
swabs [9]. PCR-positive broths were sub-cultured on blood
agar for ﬁnal identiﬁcation (ID) and antimicrobial susceptibil-
ity testing. Urine samples were spread onto Chromogenic
MRSA agar (Oxoid, Hampshire, UK) and incubated overnight
at 35C.
Veterinary samples were processed at the Faculty of Life
Sciences in Copenhagen, using their standard methods for
MRSA identiﬁcation. The overnight incubated TSB SSI broths
from companion animal samples were sub-cultured on
MRSA ID agar (bioMe´rieux, Marcy l’Etoile, France) and
blood (5%) agar. Environmental samples were processed at
the Staphylococcus Laboratory, SSI. Dip-slides from environ-
mental sampling were incubated for 42–48 h at 35C in
accordance with the manufacturer’s instructions. Presumed
staphylococcal colonies growing on the dip slides were
inoculated into the TSB SSI broth and, after overnight incu-
bation at 35C, 20 lL were sub-cultured on MRSA ID agar.
Susceptibility testing was performed on blood agar (SSI) using
an inoculum giving semi conﬂuent growth, NEO-Sensitabs
(Rosco Diagnostica, Taastrup, Denmark) and overnight
incubation. The antibiotics tested were: cefoxitin, cefuroxim,
ciproﬂoxacin, clindamycin, erythromycin, fucidic acid, genta-
micin, mupirocin, penicillin, polymyxin, rifampicin, tetra-
cycline, trimethroprim and vancomycin. Interpretation was
performed as speciﬁed by the manufacturer. (REF. Rosco’s
users guide: http://www.rosco.dk/Default.aspx?ID=198).
At Statens Serum Institut, MRSA were conﬁrmed by PCR
for mecA [10] and characterized by spa typing [11] and
SCCmec typing [12]. Selected isolates were typed by multilo-
cus sequence typing [13] and/or pulsed ﬁeld gel electropho-
resis [14].
Interventions and decolonization treatment
Households were informed of the results by telephone. In
households with MRSA-positive samples, all household mem-
bers were offered DT and instructed to start DT at the
same time (Table 1). Patients with wounds were given inten-
sive wound care to ensure healing prior to DT. Cleaning
instructions were given to all MRSA-positive households
(Table 1). If patients needed assistance with DT or cleaning
procedures, home care assistance and nursing was provided.
All expenses were paid by the local municipalities in Vejle
County. The efﬁcacy of the DT was controlled by swabbing
the nose, throat, perineum and other colonized sites on days
7, 14 and 21 after treatment. The laboratory database was
used to follow up on MRSA positive samples for the next
18 months.
Statistical analysis
Univariate analyses were performed using Statistical
Software 8 (Stata Corporation, College Station, TX, USA).
Risk ratios and 95% CI were calculated for dichotomous
variables. The multivariable model included previous infec-
tion, time since last positive sample, correct control after
last positive sample and the number of sites previously col-
onized, chronic diseases and pharyngeal carriage. Logistic
regression analyses were performed using LOGXACT, version
7.0, procedures for SAS 9.1.3 (SAS Institute Inc., Cary, NC,
USA).
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Results
Four hundred and forty persons were positive for MRSA
ST22 from November 2002 until December 2005. One
hundred and sixty-nine were deceased and 21 lived in another
county, leaving a total of 250 eligible persons of whom 102
(41%) agreed to participate. The participation rate was
slightly higher among patients (n = 83, 43%) than among
HCWs (n = 19, 34%). Among the 102 index persons, 74 (73%)
had received DT, whereas 25 had never received DT.
However, 16 of these 25 index persons had previously been
treated with other anti-MRSA treatments. For three index
persons, the previous use of DT could not be substantiated.
Among the patients and HCWs participating in the study, 38
(46%) and 12 (63%), respectively, had three sets of negative
MRSA control swabs after their last MRSA-positive test and
ﬁve patients (6%) were known long-term MRSA carriers. For
37 patients and six HCWs, some negative control swabs
existed, but not three full sets from the nose, throat and
perineum (generally, the perineal samples were missing).
Three patients had three negative sets, although sampling was
performed immediately after DT. Finally, no control samples
were taken from four patients and one HCW.
For comparative purposes, we checked the MRSA status
of the 148 persons who did not want to participate in the
study; 42 (38%) patients and 30 (81%) HCWs had three sets
of correctly taken negative control samples. In this group,
we also found that 5% of patients were long-term carriers.
Findings during the household survey and follow-up period
At the household visits, we found 12 patients and two of
their household contacts to be MRSA-positive. During fol-
low-up, four additional patients tested positive: three at
admission screening at the hospital and one at the general
practitioner’s ofﬁce. The 16 MRSA ST22-positive patients
had been intermittent or persistent carriers during 14–
41 months; all had chronic underlying conditions and a his-
tory of pharyngeal carriage (Table 2). In the patients testing
positive during the household survey, the carriage sites were
throat (75%), nose (50%) and the urinary tract (19)% (all
catheterized patients). Only three patients were multiple-site
TABLE 2. Distribution, demographics, treatment and control data prior to household survey in 83 patients and 19 healthcare
workers (HCW) with a history of methicillin-resistant Staphylococcus aureus (MRSA) ST22 infection or colonization and decol-
onization therapy
Positive patients Negative patients HCW (all negative)
Index persons 16 67 19
Households 15 64 19
Households with >1 previously positive: n (%) 3 (19) 6 (9) 1 (5)
Sex (male/female) 10/6 38/29 1/18
Year of ﬁrst positive sample: n (%)
2003 1 (6) 5 (8) 2 (11)
2004 5 (31) 17 (25) 4 (21)
2005 10 (63) 45 (67) 13 (68)
Age at household visit: median (range) 73 (54–98) 70 (3–98) 42 (25–61)
Households with pets: n (number of pets) 2 (2) 12 (13) 9 (20)
Household size: mean (range) 1 (1–2) 1 (1–4) 2 (1–5)
Sampled from all relevant sites at ﬁrst MRSA screening: n (%) 4 (25) 20 (30) 7 (37)
Previous symptomatic MRSA infection: n (%) 12 (75) 26 (39) 2 (11)
Days from ﬁrst positive sample to last positive sample: median (range) 784 (426–1248) 6 (1–1033) 1 (1–68)
Days from last positive sample to the day of the household visit: median (range) 353 (57–714) 625 (40–1459) 689 (361–1173)
Sites previously infected/colonized: median (range) 4 (1–8) 1 (1–6) 1 (1)
Pharyngeal carriage: n (%) 16 (100)a 28 (42) 2 (11)
Previous DTb
Topical: n (%) 4 (25) 41 (61) 13 (68)
Topical + systemic: n (%) 8 (50) 6 (9) 2 (11)
No DT: n (%)c 4 (25) 17 (25) 4 (21)
Unknown if DT: n (%) 3 (5)
Three sets of negative controls prior to survey: n (%) 4 (25) 34 (51) 12 (63)
Chronic disease: n (%) 16 (100) 46 (69) 0
Most frequent chronic diseases: n (%)
Cardiovascular 7 (44) 29 (43)
Chronic obstructive pulmonary disease 4 (25) 13 (19)
Diabetes 2 (13) 10 (15)
Cancer 4 (25) 10 (15)
Patients are stratiﬁed according to MRSA status in the household survey.
aOne patient only tested positive in a pooled sample from nose and throat prior to the survey, but was positive in the throat sample in the survey; the others had previously
tested positive in throat samples.
b For decolonization treatment (DT), see Table 1.
cOf the persons not having received DT; four of ﬁve positive patients, 12 of 17 negative patients and three of four HCW had received other anti-MRSA treatment. The
HCW who had not received DT was unaware of MRSA carriage because the general practitioner had misinterpreted the laboratory result.
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carriers (more than two positive sites) when tested during
the survey (see Supporting Information, Table S1). The two
positive household contacts were pharyngeal MRSA carriers
only. MRSA ST22, was found in the environment of four
households of long-term carriers: on the telephone (four
households), skirting board near bed (two households),
televison remote control (two households) and toilet ﬂush
handle (one household) (see Supporting Information,
Table S1). These four patients had all been MRSA-positive
for the last 2–3 years and none of the households had pets.
In three of the four homes, one person had previously had
an MRSA infection. Furthermore, in two of the four house-
holds, the index persons had previously tested MRSA-nega-
tive with three sets of control samples and MRSA in the
environment may have been the cause of re-colonization in
these two cases (see Supporting Information, Table S1).
None of the HCWs or their households were MRSA-posi-
tive and none of the 35 pets were MRSA-positive.
Clinical and demographic data of 83 patients and 19 health-
care workers:
No difference was observed between MRSA-positive and -
negative patients regarding DT and follow-up data (Table 2).
In the univariate analyses (Table 3), the long-term MRSA-
positive patients had more recently had a positive sample
(p 0.005), had previously had a symptomatic infection
(p 0.009), had been pharyngeal carriers (p <0.001) and had
more anatomical sites previously infected/colonized
(p <0.001). All positive patients had one or more chronic
diseases, most frequently cardiovascular disease and chronic
obstructive pulmonary disease.
In the multivariable model, only chronic diseases
(p <0.001) and pharyngeal carriage (p <0.001) were found to
be signiﬁcant risk factors for long-term MRSA carriage
(Table 3).
Because none of the HCWs were MRSA-positive in our
survey, they were not included in the statistical calculations.
All HCWs were healthy and young and had no personal risk
factors for MRSA. Compliance regarding DT and control
after DT was higher among HCWs because they were sus-
pended from work with salary until they had ﬁnished DT.
Most HCWs were only colonized in the nose and were trea-
ted promptly; the time from ﬁrst to last positive sample was
thus much shorter.
Intervention and decolonization treatment
Twelve of the 18 cases (16 patients, two relatives) testing
MRSA-positive in the present study received additional DT
along with hygiene and cleaning instructions. Four patients
were not treated because they had chronic conditions mak-
ing successful MRSA DT unrealistic (e.g. ﬁstulas from an
abdominal prolene net or supra-pubic bladder catheter).
One patient did not want DT and one patient died of pneu-
monia as a result of MRSA before anti-MRSA treatment was
implemented.
Five patients and two household contacts became
MRSA-free after a single DT. Five additional patients were
decolonized after two DTs. No pharyngeal carrier became
MRSA-free without systemic antimicrobial treatment.
Discussion
Only few studies have followed nosocomially MRSA-infected
or colonized patients after discharge from hospital [15–17]
and, except for case reports, to our knowledge, the present
study is the ﬁrst to combine follow-up of household contacts
with investigations of the home environments and compan-
ion animals.
TABLE 3. Risk factors for long-term MRSA carriage in 83
patients.
MRSA positive
patients/All
patients (%)
Risk
Ratio 95% CI P
Sex
Male 10/48 (21) 1.22 0.49–3.03 0.674
Female 6/35 (17)
Age
<70 yearsa 8/43 (19) 0.93 0.39–2.24 0.872
‡70 years 8/40 (20)
Pets in the home
Yes 2/14 (14) 0.70 0.18–2.76 0.604
No 14/69 (20)
House hold with >1 previously MRSA positive
Yes 3/9 (33) 1.90 0.67–5.41 0.258
No 13/74 (18)
Previous MRSA infection
Yes 12/38 (32) 3.55 1.25–10.11 0.009
No 4/45 (9)
Throat carriage
Yes 16b/41 (37) NDd ND <0.001*
No or unknown 0/42 (2)
Number of sites previously colonized/infected
>2 12/30 (40) 5.3 1.87–14.98 <0.001
£2 4/53 (8)
Chronic disease
Yes 16/62 (26) ND ND <0.001*
No 0/21 (0)
Time since last positive sample
<590 daysc 13/41(32) 4.44 1.36–14.44 0.005
‡590 days 3/42 (7)
Previous carrier treatment
Yes 12/59 (20) 1.22 0.44–3.41 0.701
No or unknown 4/24 (17)
Control after last treatment
Yes 4/38 (11) 0.39 0.14–1.12 0.063
No 12/45 (27)
aThe median age of all patients was 70 years.
bOne patient had prior to the household survey only been tested positive in a
pooled sample, this patient was throat positive at the household visit. All other
positive patients had throat positive samples prior to the household survey.
cThe median number of days between last MRSA positive sample and household
visit for all patients.
dND: Not deﬁned.
* Statistically signiﬁcant in the logistic regression model.
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Among patients, and in particular among HCWs, we
observed a low participation rate, and from the reply letters
from both groups, we received the impression that it was
the ‘emotional and social consequences’ of a possible MRSA-
positive test that made them reject participation. However,
during the outbreak, 81% of HCWs (non-participants) had
three correctly taken sets of samples that were negative
after DT but, among the participating HCWs, only 63% had
three correctly taken MRSA-negative control sets, which
may have motivated them to participate.
All HCWs had been successfully decolonized during the
outbreak. Among patients, however, a long-term carriage
rate of 19% was found in spite of DT as recommended by
the local MRSA guidelines. During the outbreak only the
index persons were offered MRSA DT, in disagreement with
the protocol used in the present study, where the entire
household was screened and treated simultaneously. As
shown in Table 2, in only one-third of cases were samples
taken from relevant sites when MRSA was ﬁrst detected,
which may have inﬂuenced the initial choice of the DT pro-
tocol. Furthermore, 25% of patients had not received DT
and only half of the MRSA-positive patients had previously
received treatment for pharyngeal carriage. That 25% of
patients had not received DT during the outbreak may be a
result of several factors: (i) during the ﬁrst year of the out-
break, DT was only recommended occasionally and mostly
for HCWs because it was believed that MRSA would disap-
pear when the patient was discharged from hospital; (ii)
MRSA DT was optional for patients, but not for HCWs; (iii)
the majority of patients not receiving MRSA DT had previ-
ously had an MRSA infection and did not receive MRSA DT
after treatment for their MRSA infection; (iv) some patients
had personal risk factors, which made successful MRSA
decolonization unlikely; and (v), in a few persons, coloniza-
tion with ST22 disappeared spontaneously, without DT.
It is noteworthy that the throat was the most frequent
site of colonization in patients found to be positive at the
household visit and that, in both household contacts identi-
ﬁed, the throat was the colonized site. All the long-term
MRSA-positive patients were or had at some stage been pha-
ryngeal carriers. This type of carriage now appears to be
more frequent than previously described, and the throat is a
site not to be neglected when screening for MRSA [18,19].
Mertz et al. [20] have shown that pharyngeal carriage is age-
dependant and more frequent among young people and per-
sons older than 75 years. The median age of the patients in
the present study was 73 years.
A higher detection rate in throat swabs compared to
nose swabs might be a result of the screening method used.
Solberg [21] showed that CFU counts from pharyngeal car-
riers are lower than from nasal and perineal carriers. We
used a selective enrichment broth (TSB SSI), designed for
use in the present study, which was found to allow detec-
tion of <20 CFU/mL and to increase the rate of detection
of MRSA in throat samples [22]. In addition, we used
ﬂocked swabs that were placed directly in the enrichment
broth. Despite the use of an enrichment step, four patients
found to be MRSA-negative during household screening
were found to be positive at a later date in the present
study.
Failure in detection of MRSA can be the result of several
factors, such as incorrect sampling techniques, low MRSA
numbers as a consequence of recent antibiotic treatment
(which we inquired about but which patients did not always
recall), intermittent carriage and intracellular MRSA carriage
[23].
The treatment interventions made in the present study sug-
gest that systemic treatment in addition to topical treatment
may be necessary to remove pharyngeal carriage in long-term
MRSA carriers. Failure in treating this carriage with topical
treatment has been described in other studies [24,25].
Mupirocin resistance has been shown to be associated with
treatment failure, although no mupirocin resistance was seen
during this outbreak and in the follow-up study [26].
Similar to the hospital environment, the home environ-
ment is a possible reservoir for re-colonization [1,27]. Previ-
ous studies by Solberg [21] have shown that the amount of
staphylococci dispersed to the environment vary according
to the site of colonization, infection and co-morbidity. Nasal
and perineal carriers disperse more staphylococci than pha-
ryngeal carriers, and people with chronic illnesses disperse
more than those without [21]. We took samples from ﬁve
preselected household areas, although Kniehl et al. [27] have
shown that MRSA can be found at many sites of the home.
The present study conﬁrms that, in cases of relapse after
DT, the environment should be taken into consideration
when planning for additional DT. We provided positive
households with hygiene and cleaning instructions but other
interventions (e.g. hydrogen peroxide vaporization) could
have been used [28].
We did not detect MRSA in any of the 35 companion ani-
mals examined, two of which lived in households of long-term
MRSA carriers. This result indicates that companion animals
did not play a role in the Vejle outbreak. Several studies have
shown that pet animals such as dogs and cats can be colo-
nized or infected with MRSA ST22 [2], especially in countries
where this MRSA lineage is widespread, such as in the UK.
Apart from the recent emergence of MRSA ST398 in pig
farming [29], only a few case reports have described human-
to-animal or animal-to-human MRSA transmission [30,31]. In
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most of these reports, the humans had an MRSA infection or
the environment was heavily contaminated (e.g. veterinary
hospitals contaminated by animal patients with MRSA).
Because it is reasonable to assume that patients with MRSA
are an important source of environmental contamination [21]
and that pets are more likely to be colonized when their
household environment is heavily contaminated, it should be
noted that all animals included in the present study lived in
households where no environmental MRSA contamination
was detected.
A limitation of the present study is that we used both
prospective and retrospective data. Because the MRSA-
positive patients had not been screened systematically
prior to our household visits, we could not with certainty
determine whether they were intermittent or persistent
carriers. In addition, the data on previous treatments for
carriage were not complete, primarily because the wards
in some cases had not stored records on decolonization
treatment. The response rate from general practitioners
was low and, although the patients ﬁlled in a questionnaire
regarding treatment for carriage, there might have been
recall bias. Also, the environmental Biotrace dip-slides
often showed massive growth of other bacteria and fungi,
which is one reason why MRSA may have been missed in
some cases.
In conclusion, we found that MRSA DT may have pre-
vented long-term carriage in most patients and all HCWs;
however, chronic disease and pharyngeal carriage were inde-
pendent risk factors for long-term carriage. The prevalence
of pharyngeal carriage was remarkably high and eradication
of this carriage required systemic antibiotic therapy. The
household environment was conﬁrmed to be a possible res-
ervoir for re-colonization with MRSA after DT. Companion
animals were not involved in the spread of MRSA in the
present setting.
If early intervention in the form of MRSA DT and short-
term follow-up is thorough and supervised, further house-
hold spread, infection with MRSA and long-term carriage can
be prevented. Long-term carriage increases the risk of
spread to the environment whereby the eradication of MRSA
becomes a much more complicated task.
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